**ABSTRACT**

**Background:** Profile of thoracic stentgrafts is one of the major limitations at this time. How do low profile impact on procedural results?

**Methods:** A new available low profile device (Navion, Medtronic) is analyzed in a prospective single arm multicenter trial. 30 day results are presented looking at applicability, accessibility, tractability and clinical outcomes.

**Results:** Significant design changes are responsible for profile reduction of 4 French. Reducing profile increased patient applicability to 20% and accessibility of tortuous anatomy in 87%. Conformability was maintained. SAE rate was not increased.

**Conclusions:** Early results from LP devices in TEVAR show promising results and may have major impact on feasibility. Longterm data is warranted to proof durability.

---

**PURPOSE**

To demonstrate how LP thoracic stentgrafts, increase accessibility, tractability, accurate deployment and conformability.

---

**METHODS**

Prospective multicenter single arm trial enrolled 87 patients were treated for 20.7% PAU and 79.3% TAA with Navion (Medtronic) Profile reduction up to 4 Fr. was achieved by shortening struts, redesigned RO markers, more flexible yarn and new proprietary loading process. (Fig.2)

---

**RESULTS**

Reduced profile influenced patient applicability:
- 20% more patients were treated (female, TAA)
- No access complications
- decrease iliac conduit rates percutaneous access 50%
- 100% deployment success
- 1.2% type la endoleak at 30 days
- 2.3% secondary intervention rates
- MAE 28.7% @ 30 days

---

**DISCUSSION**

- Profile (up to 4Fr.)
- Inner wall apposition in the arch (Zone 0 & 1)
- Control during deployment
- Preservation of aortic branches
- Longterm durability (migration)
- Clinical AE e.g. stroke, EL, paraplegia

---

**SUMMARY**

Reducing profile:
- increases patient applicability and accessibility in tortuous anatomy
- maintains conformability
- is responsible for significant design changes without increasing adverse events

---

**CONCLUSION**

- Low profile devices are commercially available
- Early experience is encouraging
- T/EVAR devices over 20 Fr. are quickly disappearing
- Durability is at risk but key of longterm success
- Longterm results are necessary

---

**DISCLOSURES**

Consultant: Endologix, Endomax, Gore, Medtronic
Research grant/research support: Gore, Medtronic, Siemens
Advisory Board Endologix, Gore, Medtronic, Siemens
Paid speaker: Endologix, Gore, Maquet, Medtronic, Siemens